| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | ZSTK474 | GDSC1000 | pan-cancer | AAC | -0.031 | 0.3 |
| mRNA | navitoclax:PLX-4032 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | -0.032 | 0.3 |
| mRNA | BMS-708163 | GDSC1000 | pan-cancer | AAC | -0.034 | 0.3 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | BMS-270394 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.3 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.057 | 0.3 |